Genmab A/S
NASDAQ:GMAB

Watchlist Manager
Genmab A/S Logo
Genmab A/S
NASDAQ:GMAB
Watchlist
Price: 20.65 USD 0.88% Market Closed
Market Cap: 13.1B USD
Have any thoughts about
Genmab A/S?
Write Note

EV/EBIT
Enterprise Value to EBIT

13.2
Current
23.7
Median
4.1
Industry
Lower than median
Higher than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
13.2
=
Enterprise Value
79.3B DKK
/
EBIT
6B DKK
All Countries
Close
Market Cap EV/EBIT
DK
Genmab A/S
NASDAQ:GMAB
94.2B USD 13.2
FR
Pharnext SCA
OTC:PNEXF
6T USD -217 220.6
US
Abbvie Inc
NYSE:ABBV
312.7B USD 23.6
US
Amgen Inc
NASDAQ:AMGN
158.3B USD 33.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
116.2B USD 25.3
US
Gilead Sciences Inc
NASDAQ:GILD
112.4B USD 9.9
US
Epizyme Inc
F:EPE
94.1B EUR -500.5
AU
CSL Ltd
ASX:CSL
133.6B AUD 25.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.3B USD 17.7
US
Seagen Inc
F:SGT
39.3B EUR -53
NL
argenx SE
XBRU:ARGX
34.8B EUR -76.9
EBIT Growth
DK
Genmab A/S
NASDAQ:GMAB
Average EV/EBIT: 21.2
13.2
91%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -217 220.6 N/A
US
Abbvie Inc
NYSE:ABBV
23.6
88%
US
Amgen Inc
NASDAQ:AMGN
33.1
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.3
44%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -500.5 N/A
AU
CSL Ltd
ASX:CSL
25.3
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.7
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.9 N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
12.9
2-Years Forward
EV/EBIT
9.9
3-Years Forward
EV/EBIT
7.8

See Also

Discover More